Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 6/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | IL2RA | P01589 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | IL2 | P60568 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651907 | 0.84 | MMP2 (0.39) | GCKMMP2MMP9MMP12ACACB | |
| SCHEMBL2651185 | 0.84 | ACACB (0.43) | MMP2MMP9MMP12ACACB | |
| SCHEMBL2650114 | 0.83 | CYP2D6 (0.42) | GCKMMP2MMP9MMP12ACACB | |
| SCHEMBL2647677 | 0.83 | TSHR (0.46) | ESR1ESR2SLC6A3 | |
| SCHEMBL2651252 | 0.82 | FFAR1 (0.43) | GCKMMP2MMP9MMP12ACACB | |
| SCHEMBL2653693 | 0.81 | ALDH1A1 (0.40) | GCKMMP2MMP9MMP12ACACB | |
| SCHEMBL2650869 | 0.81 | ACACB (0.38) | GCKMMP2MMP9MMP12ACACB | |
| SCHEMBL2651862 | 0.80 | MMP2 (0.35) | GCKMMP2MMP9MMP12ACACB | |
| SCHEMBL2651162 | 0.80 | ALDH1A1 (0.46) | MMP2MMP9MMP12SLC6A3L3MBTL1 | |
| SCHEMBL2652587 | 0.79 | MMP2 (0.43) | MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282612-B1 | ALKYNYL PHENYL HETEROAROMATIC GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-12-29 | — | — | EP | disclosed |
| EP-1282612-A2 | ALKYNYL PHENYL HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | disclosed |
| US-6388071-B2 | ANTIDIABETIC AGENTS | HOFFMANN-LA ROCHE INC. | 2002-05-14 | — | — | US | disclosed |
| US-20010053851-A1 | Alkynyl phenyl heteroaromatic glucokinase activators | HOFFMAN-LA ROCHE INC. | 2001-12-20 | — | — | US | disclosed |
| WO-2001083465-A2 | ALKYNYL PHENYL HETEROAROMATIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053851-A1 | Alkynyl phenyl heteroaromatic glucokinase activators | GCK, GCKR, HK2 | GCK 1/4885MMP2 947/4885MMP9 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.